Resveratrol, a constituent of grapes and other foods, has been reported to be a potential cancer chemopreventive agent. Our previous study showed that the antitumor activity of resveratrol occurs through mitogen-activated protein kinases-mediated p53 activation and induction of apoptosis. To develop more effective agents with fewer side effects for the chemoprevention of cancer, we investigated the effect of resveratrol and its structurally related derivatives on epidermal growth factor (EGF)-induced cell transformation. Our results provided the first evidence that one of the resveratrol derivatives exerted a more potent inhibitory effect than resveratrol on EGF-induced cell transformation, but had less cytotoxic effects on normal nontransformed cells. Compared to resveratrol, this compound also caused cell cycle arrest in the G1 phase, but did not induce p53 activation and apoptosis. Furthermore, this compound, but not resveratrol, markedly inhibited EGF-induced phosphatidylinositol-3 kinase (PI-3K) and Akt activation. Collectively, these data suggested that the higher antitumor effect of the compound compared to resveratrol, may act through a different mechanism by mainly targeting PI-3K/Akt signaling pathways.
|Number of pages||8|
|State||Published - Apr 10 2003|
Bibliographical noteFunding Information:
We thank Dr Ann M Bode for critical reading of the manuscript, Patricia Schmid for analysis of cell cycle and apoptosis, Qing Ye for help with some experiments and Andria Hansen for secretarial assistance. This work was supported in part by The Hormel Foundation, American Institutes for Cancer Research Grant 99A062, and National Institutes of Health Grants CA77646 and CA81064.
- Cell transformation
- Resveratrol derivatives
ASJC Scopus subject areas
- Molecular Biology
- Cancer Research